U.S. markets close in 4 hours 3 minutes
  • S&P 500

    3,623.83
    -11.58 (-0.32%)
     
  • Dow 30

    29,869.50
    -176.74 (-0.59%)
     
  • Nasdaq

    12,046.83
    +10.04 (+0.08%)
     
  • Russell 2000

    1,840.44
    -13.09 (-0.71%)
     
  • Crude Oil

    45.56
    +0.65 (+1.45%)
     
  • Gold

    1,809.40
    +4.80 (+0.27%)
     
  • Silver

    23.40
    +0.10 (+0.43%)
     
  • EUR/USD

    1.1910
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    0.8680
    -0.0140 (-1.59%)
     
  • GBP/USD

    1.3376
    +0.0018 (+0.13%)
     
  • USD/JPY

    104.4070
    -0.0730 (-0.07%)
     
  • BTC-USD

    19,019.64
    -247.00 (-1.28%)
     
  • CMC Crypto 200

    377.07
    +6.55 (+1.77%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Recap: Ascendis Pharma Q3 Earnings

Benzinga Insights
·1 min read

Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 365.52% over the past year to ($2.70), which missed the estimate of ($1.86).

Revenue of $3,222,000,000 rose by 143546.90% year over year, which beat the estimate of $1,660,000.

Looking Ahead

Ascendis Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 11, 2020

View more earnings on ASND

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/bu6b6ks2

Recent Stock Performance

Company's 52-week high was at $178.25

52-week low: $92.00

Price action over last quarter: Up 14.98%

Company Description

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.